Searching…
May 31, 2023 · Background: First line BRAFi/MEKi therapy in metastatic melanoma eventually result in drug resistance and disease progression. Because drug resistance develops at least partially by epigenetic mechanism...
Many BRAF inhibitors (BRAFi) have been developed and approved by the US Food and Drug Administration (FDA), including vemurafenib, dabrafenib, and encorafenib. However, resistance to BRAFi develops quickly, with a med...
Background: BRAF and MEK inhibitors (BRAFi/MEKi) offer high response rates and rapid tumor regression in BRAF-mutant metastatic melanoma. However, objective responses have a median duration of only 12 months. Approxim...
BRAFi PF-07799933 is an investigational compound. Its safety and efficacy have not been established.
BRAFi cause increased expression of melanocyte differentiation antigens, increased recognition by antigen-specific T cells, increased CD8 + T-cell infiltration in the melanoma microenvironment, decreased expression of...
Jan 10, 2024 · This study confirms that patients with advanced melanoma derive benefit from rechallenge with BRAFi(/MEKi). Elevated lactate dehydrogenase levels, symptomatic brain metastases, and discontinuing firs...
Dec 14, 2020 · BRAF inhibitors (BRAFi) and MEK inhibitors (MEKi) significantly improved metastatic melanoma prognosis. Ocular adverse effects (OAEs) represent an uncommon but disabling toxicity of these drugs. We aime...
Jun 17, 2025 · This study addresses the urgent need to develop treatments for BRAFi+MEKi-resistant glioma using preclinical mouse models and patient-derived materials. BRAFi+MEKi reveals glioma plasticity by heighteni...
May 31, 2023 · Rechallenging patients with BRAFi/MEKi may be an alternative to overcome resistance and improve outcomes. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of BRAFi/...
Combinations of BRAF inhibitors and MEK inhibitors (BRAFi + MEKi) are FDA-approved to treat BRAF V600E/K -mutant melanoma. Efficacy of BRAFi + MEKi associates with cancer cell death and alterations in the tumor immune...
